secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001171843-24-006089
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cassava Sciences reports Q3 net loss $27.9M; RETHINK-ALZ top-line data expected by end-2024
--------------------------------------------------------------------------------

- Net loss $27.9M ($0.58 per share) vs $25.7M ($0.61) in Q3 2023; cash $149M at Sep 30, 2024.
- Top-line results from Phase 3 RETHINK-ALZ trial (simufilam) expected before end of 2024.
- DSMB recommended both Phase 3 studies continue as planned at Sep 2024 meeting.
- Year-end 2024 cash estimated $117-127M; $40M SEC settlement in escrow excluded.
- Open-label extension study enrolled over 1,040 patients; 88% opt-in rate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000117184324006089/0001171843-24-006089-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000117184324006089/f8k_110724.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-006089

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer